Decision analysis supports the paradigm that indiscriminate supplementation of vitamin e does more harm than good

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 9, 2009, Pages 1304-1309

  Dotan, Yedidya ^a   Pinchuk, Ilya ^a   Lichtenberg, Dov ^a   Leshno, Moshe ^b  

^a Department of Physiology and Pharmacology ^*  (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CVD; Decision analysis; Markov model; Oxidative stress; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; HEART INFARCTION; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SIMULATION; STATISTICAL MODEL; STROKE; VITAMIN SUPPLEMENTATION; ADULT; ATHEROSCLEROSIS; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MARKOV CHAINS; META-ANALYSIS AS TOPIC; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; VITAMIN E;

EID: 69849104510     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.178699     Document Type: Article

References (47)

1. Williams KJ, Fisher EA. Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? Curr Opin Clin Nutr Metab Care. 2005;8:139-146.
2. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001; 11:93-102.
3. Jha P, Flather M. The antioxidant vitamins and cardiovascular disease. Ann Intern Med. 1995;123:860-872.
4. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Randomised trial of a-tocopherol and /3-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715-1720.
5. Stephens NG, Parsons A, Brown MJ, Schofield PM, Kelly F, Cheeseman K, Mitchinson M. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
6. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356: 1213-1218.
7. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65. (Pubitemid 41002839)
8. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Vouti-lainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003;107:947-953.
9. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-2023.
10. Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu W, Suttorp J, Coulter I, Newberry SJ, Hardy M. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004;19:380-389.
11. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364:1219-1228.
12. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297:842-857.
13. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
14. Miller ER, III, Appel LJ, Guallar E, Pastor-Barriuso R. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:156-158.
15. Correa P, Fontham E, Bravo LE, Mera R. Antioxidant supplements for prevention of gastrointestinal cancers. Lancet. 365:470.
16. Krishnan K, Campbell S, Stone WL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151.
17. Meydani SN, Lau J, Dallal GE, Meydani M. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:153.
18. Lim WS, Liscic R, Xiong C, Morris JC. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:152.
19. Jialal I, Devaraj S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155.
20. Forman D, Altman D. Vitamins to prevent cancer: supplementary problems. The Lancet. 364:1193-1194.
21. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:1043-1053.
22. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
23. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998;158: 655-662.
24. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156:761-773.
25. Unal B, Capewell S, Critchley JA. Coronary heart disease policy models: a systematic review. BMC Public Health. 2006;6:213.
26. Sesso HD, Chen RS, Italien GJ, Lapuerta P, Lee WC, Glynn RJ. Blood pressure lowering and life expectancy based on a Markov model of cardiovascular events. Hypertension. 2003;01.
27. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis Making. 1997;17:152-159. (Pubitemid 27157030)
28. Muennig PA, Gold MR. Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001;20:35-39.
29. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3-Estimating probabilities and utilities. Med Decis Making. 1997;17:136-141. (Pubitemid 27157028)
30. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272-281.
31. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction: a population-based study. Stroke. 1997;28:762-767.
32. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JNE, Bull LM, Welch SJV, Cuthbertson FC. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 366:1773-1783.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-1788.
34. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123-127.
35. Bennett K, Kabir Z, Unal B, Shelley E, Critchley J, Perry I, Feely J, Capewell S. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health. 2006;60:322-327.
36. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med. 1994;120:449-457.
37. Hunink M, Glasziou P. Variability and uncertainty. Decision MAKING in Health and Medicine. paperback ed. Cambridge University Press. 2001: 339-363
38. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med. 1998;339: 380-386.
39. Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making. 2001;21:288-294.
40. Witztum JL. To E or not to E-how do we tell? Circulation. 1998; 98:2785.
41. Blatt DH, Pryor WA. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:150-151.
42. Hemila H. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151-a.
43. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, and Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28: 341-347.
44. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Hapto-globin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435-441.
45. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res. In press.
46. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478.
47. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA. 2001;285: 1178-1182.